Business Context and Reporting Period
RXi Pharmaceuticals Corporation (filing as Phio Pharmaceuticals Corp. in metadata) submitted this Form 8-K on August 13, 2013. The report covers the quarter ended June 30, 2013, and details a specific corporate action regarding equity securities executed on August 13, 2013.
Key Financial Metrics
This filing serves as a notification of the release of quarterly results and a specific equity transaction. The text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained in the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Actions
- Equity Exchange: On August 13, 2013, the Company entered into an Exchange Agreement with Tang Capital Partners, L.P. (TCP).
- Stock Conversion: TCP exchanged 2,000 shares of Series A Preferred Stock for 2,000 shares of a newly designated Series A-1 Convertible Preferred Stock.
- Term Modification: The Series A-1 Preferred Stock terms are identical to the Series A Preferred Stock, except for the elimination of cash penalties that would otherwise be due if the Company failed to have enough Common Stock available for conversion.
- Regulatory Status: The issuance was unregistered, relying on the Section 3(a)(9) exemption of the Securities Act of 1933 for exchanges with existing security holders.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, or a detailed risk assessment within the text provided. It notes that the information regarding the results of operations (Item 2.02) is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in a future filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2013) for actual financial performance metrics for the quarter ended June 30, 2013.
- Verify the total outstanding shares of Series A and Series A-1 Preferred Stock to assess dilution potential.
- Confirm the Company's current Common Stock availability to ensure future conversion of preferred shares is not impeded.
- Check subsequent filings for any incorporation of the Item 2.02 results by reference.